Search clinical trials for: mirror-box treatment

Total 14239 results

National Cancer Institute (NCI)

Recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Stage IV Ovarian Cancer AJCC v8 | Ovarian Low Grade Serous Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Neurofibromatosis Type 1 | Metastatic Malignant Peripheral Nerve Sheath Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor

United States
Yuanquan Yang

Not yet recruiting

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Advanced Malignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Metastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study

Malignant Glioma

United States
National Cancer Institute (NCI)

Suspended

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Locally Advanced Leiomyosarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Locally Advanced Liposarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Locally Advanced Extraskeletal Myxoid Chondrosarcoma | Locally Advanced Unresectable Soft Tissue Sarcoma

United States, Canada
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
University of the Philippines

Completed

Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study

Retinopathy of Prematurity
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Acute Myeloid Leukemia | Secondary Myelofibrosis | Acute Myeloid Leukemia in Remission | Primary Myelofibrosis, Prefibrotic Stage

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (OPTION-VMS)

Hot Flashes

United States
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Lymphoma

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Completed

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chemotherapy-sensitive Lymphoma | Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma | Acute Biphenotypic Leukemia (ABL) | Acute Undifferentiated Leukemia (AUL)

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Gliosarcoma | MGMT-Unmethylated Glioblastoma

United States
University of Washington
National Cancer Institute (NCI); Seagen Inc.

Active, not recruiting

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
City Hospital No 40, Saint Petersburg, Russia

Withdrawn

Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy (CSWTSPB40)

Coronary Heart Disease (CHD)
St. Jude Children's Research Hospital

Terminated

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Hematological Malignancies

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Crohn's Allogeneic Transplant Study (CATS)

Crohn Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
Case Comprehensive Cancer Center

Completed

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central Chondrosarcoma

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Washington
Janssen Scientific Affairs, LLC

Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Withdrawn

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Pancreatic Adenocarcinoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Malignant Solid Neoplasm | Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage... and other conditions

United States
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Clinical Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Recurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States

Search clinical trials for: mirror-box treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations